Key risks
Valuation risk: PE of 39.98 against near-flat revenue (₹1,434–1,603 Cr over recent 12 quarters) and EPS that peaked at ₹14.52 (Sep 2024) but has since declined to ₹12.61 (Jun 2026). Verify whether the market is pricing in future growth that is not yet visible.
Margin compression trend: OPM peaked at 34.05% in Mar 2025 and has since fallen to 29.74% (Dec 2025) and 30.12% (Jun 2026). Determine whether this reflects input cost pressure, pricing constraints, or product mix shift.
No apparent revenue growth: Standalone revenue is flat or slightly up (Jun 2026 ₹1,603 is +11.8% YoY, but intervening quarters show no consistent acceleration). Verify whether oral care category is mature and organic growth is limited.
Stock performance disconnect: 1-year return of −11.57% despite ROE of 81.59% and zero debt suggests investor skepticism on growth or valuation sustainability.
Generated analysis · source review pending